Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study (vol 8, e000331, 2020)

被引：0
|
作者：
Najjar, Y. G.
Navrazhina, K.
Ding, F.
Puzanov, Igor
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷 / 02期
关键词：
D O I：
10.1136/jitc-2019-000331corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases
    Fujisawa, Yasuhiro
    Namikawa, Kenjiro
    Yoshino, Koji
    Kiniwa, Yukiko
    Ito, Takamichi
    Kato, Hiroshi
    Matsushita, Shigeto
    Hoashi, Toshihiko
    Nakamura, Yasuhiro
    Yoshikawa, Shusuke
    Miyagawa, Takuya
    Asai, Jun
    Matsuya, Taisuke
    Fukushima, Satoshi
    Kato, Jyunji
    Takenouchi, Tatsuya
    Uchi, Hiroshi
    Masuzawa, Mamiko
    Yanagi, Teruki
    Maekawa, Takeo
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (02) : 223 - +
  • [42] Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study
    Koichi Kido
    Shingo Hatakeyama
    Kazuyuki Numakura
    Toshikazu Tanaka
    Masaaki Oikawa
    Daisuke Noro
    Shogo Hosogoe
    Shintaro Narita
    Takamitsu Inoue
    Takahiro Yoneyama
    Hiroyuki Ito
    Shoji Nishimura
    Yasuhiro Hashimoto
    Toshiaki Kawaguchi
    Tomonori Habuchi
    Chikara Ohyama
    International Journal of Clinical Oncology, 2021, 26 : 154 - 162
  • [43] Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study
    Iinuma, Koji
    Kameyama, Koji
    Taniguchi, Tomoki
    Kawada, Kei
    Ishida, Takashi
    Takagi, Kimiaki
    Nagai, Shingo
    Enomoto, Torai
    Tomioka, Masayuki
    Kawase, Makoto
    Takeuchi, Shinichi
    Kato, Daiki
    Takai, Manabu
    Nakane, Keita
    Koie, Takuya
    CANCERS, 2022, 14 (19)
  • [44] Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study
    Kido, Koichi
    Hatakeyama, Shingo
    Numakura, Kazuyuki
    Tanaka, Toshikazu
    Oikawa, Masaaki
    Noro, Daisuke
    Hosogoe, Shogo
    Narita, Shintaro
    Inoue, Takamitsu
    Yoneyama, Takahiro
    Ito, Hiroyuki
    Nishimura, Shoji
    Hashimoto, Yasuhiro
    Kawaguchi, Toshiaki
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 154 - 162
  • [45] Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
    Piulats, J. M.
    Watkins, C.
    Costa-Garcia, M.
    del Carpio, L.
    Piperno-Neumann, S.
    Rutkowski, P.
    Hassel, J. C.
    Espinosa, E.
    de la Cruz-Merino, L.
    Ochsenreither, S.
    Shoushtari, A. N.
    Orloff, M.
    Salama, A. K. S.
    Goodall, H. M.
    Baurain, J. -F.
    Nathan, P.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 317 - 326
  • [46] Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) plus ipilimumab (ipi) plus external beam radiotherapy (RT) in patients with metastatic melanoma.
    Postow, Michael A.
    Knox, Susan Jane
    Goldman, Debra
    Panageas, Katherine
    Halpenny, Darragh
    McCabe, Danielle
    Macri, Mary J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    Barker, Christopher Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
    Di Giacomo, A. M.
    Simonetti, E.
    Calabro, L.
    Vegni, V.
    Santangelo, F.
    Depenni, R.
    Colucci, M.
    Valente, M.
    Grifoni, R.
    Lofiego, M. F.
    Amato, G.
    Keer, H. N.
    Oganesian, A.
    Chan, D.
    Giannarelli, D.
    Altomonte, M.
    Ceccarelli, M.
    Anichini, A.
    Covre, A.
    Maio, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1237 - 1237
  • [48] Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma
    Gibney, Geoffrey Thomas
    Pecora, Andrew L.
    Rapisuwon, Suthee
    Chen, Kevin
    Gardner, Kellie
    Cramer, Gayle
    Blair, Danielle
    Avergas, Amy
    Swanson, Nicole
    Ahn, Jaeil
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study
    Hindso, Tine G.
    Jensen, Peter S.
    Sjol, Mette B.
    Nissen, Kristoffer
    Bjerrum, Camilla W.
    von Benzon, Eric
    Faber, Carsten
    Urbak, Steen F.
    Donia, Marco
    Svane, Inge M.
    Ellebaek, Eva
    Heegaard, Steffen
    Madsen, Karine
    Kiilgaard, Jens F.
    CANCERS, 2024, 16 (19)
  • [50] Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study
    Izumi, Keita
    Inoue, Masaharu
    Washino, Satoshi
    Shirotake, Suguru
    Kagawa, Makoto
    Takeshita, Hideki
    Miura, Yuji
    Hyodo, Yoji
    Oyama, Masafumi
    Kawakami, Satoru
    Miyagawa, Tomoaki
    Saito, Kazutaka
    Kageyama, Yukio
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 714 - 721
12345